Comparative Study of the Effects of Atypical Antipsychotic Drugs on Plasma and Urine Biomarkers of Oxidative Stress in Schizophrenic Patients

• Published in: Neuropsychiatric disease and treatment Vol. 17; pp. 555 - 565
• Main Authors: Dietrich-Muszalska, Anna, Kolodziejczyk-Czepas, Joanna, Nowak, Pawel
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2021; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Acids; Analgesics; Analysis; Animal cognition; Antioxidants; Antipsychotic drugs; Antipsychotics; Aripiprazole; Biological markers; Biomarkers; Clozapine; Comparative studies; Complications and side effects; Consent; Disease; Dopamine; Drug therapy; Dyskinesia; Enzymes; f2-isoprostanes; Hypotheses; Immunoassay; Isoprostanes; Laboratories; Lipid peroxidation; Lipids; Mental disorders; Nitrotyrosine; Olanzapine; Original Research; other oxidative markers; Oxidative stress; Patient outcomes; Plasma; Psychopathology; Psychotropic drugs; Quantitative psychology; Quetiapine; Risperidone; Schizophrenia; Spectrophotometry; tac; Thiobarbituric acid; Urine; Ziprasidone; Poland; antipsychotics; other oxidative markers; schizophrenia; F2-isoprostanes; TAC
• ISSN: 1178-2021; 1176-6328; 1178-2021
• DOI: 10.2147/NDT.S283395

Evidence that antipsychotic drugs (ADs) can affect oxidative stress estimated with various biomarkers in schizophrenic patients is controversial and limited. Therefore, in the present study, we assessed the ability of six atypical ADs (clozapine, olanzapine, quetiapine, risperidone, aripiprazole, and ziprasidone) used in schizophrenia treatment to modulate oxidative damage to different biomolecules such as lipids and proteins. We measured the levels of oxidative stress markers in plasma and urine: total antioxidant capacity by FRAP (according to a modified method of Benzie & Strain), thiobarbituric acid reactive species - TBARS (spectrophotometric method), 4-hydroxy-2-nonenal (4-HNE) (OxiSelect™ HNE Adduct Competitive ELISA Kit), 3-nitrotyrosine (3-NT) (OxiSelect™ Nitrotyrosine ELISA Kit) in plasma, and F2-isoprostanes (BIOXYTECH Urinary 8-epi-Prostaglandin F2α) in the urine of 60 schizophrenic patients (before and after treatment) and in 30 healthy subjects. Our results showed that in schizophrenic patients levels of lipid peroxidation markers (TBARS, F2-isoprostanes) were higher than in healthy subjects but FRAP in schizophrenic patients was lower than in healthy controls and increased after 4-week treatment with tested ADs. A 4-week treatment with ADs caused the improvement of psychopathology symptoms estimated by Positive and Negative Syndrome Scale (PANSS) that was accompanied by decreased lipid peroxidation (F2-isoprostanes, TBARS; p=2.9x10 , p=7.6x10 , respectively) and an increase in total antioxidative capacity (FRAP) (p=5.16x10 ). Atypical antipsychotics especially clozapine, olanzapine and quetiapine demonstrate the effective outcome of antipsychotic treatment, beneficial antioxidative action by reducing lipid peroxidation and increased total plasma antioxidant activity.